Mycophenolate mofetil showed no clear difference in overall survival compared with methotrexate (low certainty).
It is very uncertain whether mycophenolate mofetil changes prevention of acute GVHD grade II to IV compared with methotrexate (very low certainty).
Mycophenolate mofetil showed no clear difference in incidence of relapse compared with methotrexate (low certainty).
Mycophenolate mofetil showed no clear difference in nonrelapse mortality compared with methotrexate (low certainty).
Mycophenolate mofetil showed no clear difference in prevention of chronic GVHD compared with methotrexate (low certainty).
Mycophenolate mofetil may leads to lower incidence of severe mucositis compared with methotrexate (low certainty).
Mycophenolate mofetil may leads to lower use of total parenteral nutrition compared with methotrexate (low certainty).
Mycophenolate mofetil may leads to lower incidence of narcotic use for pain control compared with methotrexate (low certainty).